222 related articles for article (PubMed ID: 26375848)
1. Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.
Strope SA; Vetter J; Elliott S; Andriole GL; Olsen MA
Urology; 2015 Dec; 86(6):1115-22. PubMed ID: 26375848
[TBL] [Abstract][Full Text] [Related]
2. Impact of medical therapy on transurethral resection of the prostate: two decades of change.
Izard J; Nickel JC
BJU Int; 2011 Jul; 108(1):89-93. PubMed ID: 20883490
[TBL] [Abstract][Full Text] [Related]
3. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
4. Treatment of benign prostatic hyperplasia.
Pinheiro LC; Martins Pisco J
Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
[TBL] [Abstract][Full Text] [Related]
5. Lower urinary tract symptoms in men.
Hollingsworth JM; Wilt TJ
BMJ; 2014 Aug; 349():g4474. PubMed ID: 25125424
[TBL] [Abstract][Full Text] [Related]
6. Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia.
Jovanović M; Džamić Z; Aćimović M; Kajmaković B; Pejčić T
Acta Chir Iugosl; 2014; 61(1):57-61. PubMed ID: 25782227
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
Elshal AM; Elmansy HM; Elhilali MM
BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
[TBL] [Abstract][Full Text] [Related]
8. A 10-year follow-up after transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia; long-term results of a randomized controlled trial.
Hoekstra RJ; Van Melick HH; Kok ET; Ruud Bosch JL
BJU Int; 2010 Sep; 106(6):822-6. PubMed ID: 20184573
[TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease, preoperative use of antispasmodics and lower resected prostate volume ratios are risk factors for postoperative use of adrenergic Alpha-blockers and antispasmodics.
Hsueh CH; Chang LW; Chiu KY; Hung SC; Chen JP; Li JR
PLoS One; 2023; 18(3):e0282745. PubMed ID: 36893185
[TBL] [Abstract][Full Text] [Related]
10. [Update on current care guidelines: benign prostatic hyperplasia].
Tammela T; Nurmi M; Pétas A; Sipilä R; Taari K
Duodecim; 2012; 128(10):1046-7. PubMed ID: 22724320
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
Erman A; Masucci L; Krahn MD; Elterman DS
BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
[TBL] [Abstract][Full Text] [Related]
12. Benign prostatic hyperplasia. Practical treatment guidelines.
Tammela T
Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
[TBL] [Abstract][Full Text] [Related]
13. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
Sausville J; Naslund M
Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
15. BPH update: medical versus interventional management.
Blankstein U; Van Asseldonk B; Elterman DS
Can J Urol; 2016 Feb; 23(Suppl 1):10-5. PubMed ID: 26924590
[TBL] [Abstract][Full Text] [Related]
16. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy.
Campbell J; Reid J; Ordon M; Welk B
Urology; 2019 Aug; 130():126-131. PubMed ID: 31129193
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of transurethral resection of the prostate and combined transurethral resection and vaporization of the prostate as a therapeutic alternative in men with benign prostatic hyperplasia.
Küpeli S; Yilmaz E; Soygür T; Budak M
J Endourol; 2001 Apr; 15(3):317-21. PubMed ID: 11339401
[TBL] [Abstract][Full Text] [Related]
18. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
[TBL] [Abstract][Full Text] [Related]
20. Trends and Utilization of Laser Prostatectomy in Ambulatory Surgical Procedures for the Treatment of Benign Prostatic Hyperplasia in New York State (2000-2011).
Chughtai BI; Simma-Chiang V; Lee R; Isaacs A; Te AE; Kaplan SA; Sedrakyan A
J Endourol; 2015 Jun; 29(6):700-6. PubMed ID: 25353692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
